Intralesional steroid injection for proliferative parotid hemangiomas.
OBJECTIVE
To evaluate the efficacy of proliferative phase intralesional steroid injections in the treatment of parotid hemangiomas.


METHODS
Retrospective analysis of pediatric patients with parotid hemangiomas treated with intralesional steroid injections during the proliferative phase.


METHODS
Vascular Anomalies Center, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USA.


METHODS
Twenty-one pediatric patients, ages 4-39 months.


METHODS
Between 2001 and 2006, 21 patients received steroid injections for 23 parotid hemangiomas (bilateral in 2 patients). A total of 1-3 injections over the first year of life were given at 6-25 week intervals.


RESULTS
Main outcome measures included softening, decreased growth rate, and/or decrease in size. After injection, achievement of outcome measures occurred with all lesions. No incidence of tissue atrophy or facial nerve injury was seen. Four of 21 (19%) patients developed failure to thrive (FTT).


CONCLUSIONS
Parotid hemangiomas can be effectively controlled with proliferative phase intralesional steroid injections. Injections may limit the need for future extensive surgery. Further prospective randomized trials are needed to support these claims. Failure to thrive may be a potential complication of intralesional steroid injection. Endocrine/growth monitoring should be considered when treating with intralesional steroids.
Buckmiller
Lisa M
LM
Vascular Anomalies Center, University of Arkansas for Medical Sciences, Arkansas, Children's Hospital, Little Rock, AR, USA.
Francis
Carrie L
CL
Glade
Robert S
RS
D001623:Betamethasone / Q000008:administration & dosage*; D002675:Child, Preschool; D004338:Drug Combinations; D005938:Glucocorticoids / Q000008:administration & dosage*; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D010307:Parotid Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage*
D004338:Drug Combinations; D005938:Glucocorticoids; D014221:Triamcinolone; D001623:Betamethasone